clinical studies on the MindBody GLP-1 System include: Over 200% average increase in GLP-1 over 12 weeks Average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds , Up to 9% decrease in total body fat percentage , Up to 24% decrease in visceral fat , Up to 9% decrease in subcutaneous fat , Up to 6% increase in skeletal muscle 100% of weight lost was from fat, not muscle , In addition to these physical results, participants reported notable changes in their relationship with food: 95% reported decreased sugar cravings 89% reported decreased fast-food cravings 86% reported decreased cravings for salt and soda 85% now eat for health instead of emotions 81% reported increased ability to resist snacking 89% ate less at meals 86% reported feeling less hungry Additionally, LifeVantage completed an independent 12-week human clinical trial of the international formula, known as the MB System, affirming the Companys commitment to science-backed innovation across global markets

Mechanistically, excessive fat deposition in the upper airway that impinges on the tracheal lumen through external pressure increases the likelihood of upper airway collapse in OSA [52]
Here too, the overall ANOVA p value was significant, 0.0002, indicating that the distribution between Test One, Two and Three was non-random
ODS 2023
It is highly recommended that any obesity management solution that includes GLP-1 medications have the appropriate wraparound care to ensure long-term success
Diabetes 53:410417